590 related articles for article (PubMed ID: 16783341)
1. Rational design of inhibitors that bind to inactive kinase conformations.
Liu Y; Gray NS
Nat Chem Biol; 2006 Jul; 2(7):358-64. PubMed ID: 16783341
[TBL] [Abstract][Full Text] [Related]
2. Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations.
Simard JR; Getlik M; Grütter C; Schneider R; Wulfert S; Rauh D
J Am Chem Soc; 2010 Mar; 132(12):4152-60. PubMed ID: 20201574
[TBL] [Abstract][Full Text] [Related]
3. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
4. Displacement assay for the detection of stabilizers of inactive kinase conformations.
Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
[TBL] [Abstract][Full Text] [Related]
5. Sequence, structure, and active site analyses of p38 MAP kinase: exploiting DFG-out conformation as a strategy to design new type II leads.
Badrinarayan P; Sastry GN
J Chem Inf Model; 2011 Jan; 51(1):115-29. PubMed ID: 21141877
[TBL] [Abstract][Full Text] [Related]
6. A pharmacophore map of small molecule protein kinase inhibitors.
McGregor MJ
J Chem Inf Model; 2007; 47(6):2374-82. PubMed ID: 17941626
[TBL] [Abstract][Full Text] [Related]
7. Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors.
Schneider G; Geppert T; Hartenfeller M; Reisen F; Klenner A; Reutlinger M; Hähnke V; Hiss JA; Zettl H; Keppner S; Spänkuch B; Schneider P
Future Med Chem; 2011 Mar; 3(4):415-24. PubMed ID: 21452978
[TBL] [Abstract][Full Text] [Related]
8. A general strategy for creating "inactive-conformation" abl inhibitors.
Okram B; Nagle A; Adrián FJ; Lee C; Ren P; Wang X; Sim T; Xie Y; Wang X; Xia G; Spraggon G; Warmuth M; Liu Y; Gray NS
Chem Biol; 2006 Jul; 13(7):779-86. PubMed ID: 16873026
[TBL] [Abstract][Full Text] [Related]
9. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
[TBL] [Abstract][Full Text] [Related]
10. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
Bogoyevitch MA; Fairlie DP
Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
[TBL] [Abstract][Full Text] [Related]
11. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase.
Frembgen-Kesner T; Elcock AH
J Mol Biol; 2006 May; 359(1):202-14. PubMed ID: 16616932
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.
Foster R; Griffith R; Ferrao P; Ashman L
J Mol Graph Model; 2004 Oct; 23(2):139-52. PubMed ID: 15363456
[TBL] [Abstract][Full Text] [Related]
13. Drug discovery process for kinase inhibitors.
Weinmann H; Metternich R
Chembiochem; 2005 Mar; 6(3):455-9. PubMed ID: 15742380
[No Abstract] [Full Text] [Related]
14. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches.
Vieth M; Erickson J; Wang J; Webster Y; Mader M; Higgs R; Watson I
J Med Chem; 2009 Oct; 52(20):6456-66. PubMed ID: 19791746
[TBL] [Abstract][Full Text] [Related]
15. New protein kinase CK2 inhibitors: jumping out of the catalytic box.
Prudent R; Cochet C
Chem Biol; 2009 Feb; 16(2):112-20. PubMed ID: 19246001
[TBL] [Abstract][Full Text] [Related]
16. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
Verkhivker GM
Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
[TBL] [Abstract][Full Text] [Related]
17. Structural biology contributions to tyrosine kinase drug discovery.
Cowan-Jacob SW; Möbitz H; Fabbro D
Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2.
Xie QQ; Xie HZ; Ren JX; Li LL; Yang SY
J Mol Graph Model; 2009 Feb; 27(6):751-8. PubMed ID: 19138543
[TBL] [Abstract][Full Text] [Related]
19. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
[TBL] [Abstract][Full Text] [Related]
20. Target-family-oriented focused libraries for kinases--conceptual design aspects and commercial availability.
Prien O
Chembiochem; 2005 Mar; 6(3):500-5. PubMed ID: 15742385
[No Abstract] [Full Text] [Related]
[Next] [New Search]
